文献速递慢性肾脏病血液净化与透析肾移植

全表型组关联分析提示APOL1高危变异主要通过肾脏特异性通路驱动疾病谱

Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.
PubMed 文献 · Kidney Int · 2020-02-17

该研究采用基因型优先的全表型组关联分析,在1837名Penn Medicine Biobank和4742名Vanderbilt BioVU的非裔美国参与者中,评估APOL1高危变异与多种表型的关联。Meta分析显示,APOL1高危变异与「肾脏透析」(OR 3.75)和「终末期肾病」(OR 3.42)诊断代码关联最强;在控制慢性/终末期肾病状态后,非肾脏表型均无显著关联。Penn Medicine Biobank中,APOL1高危状态与 prevalent 慢性/终末期肾病/肾移植相关(OR 2.27,95%CI 1.67-3.08),且高危参与者eGFR较低(15.4 mL/min/1.73m2)。结论提示APOL1高危变异虽与多种表型相关,但其他表型风险较低且主要由肾脏疾病驱动。

要点

  • APOL1高危变异与透析(OR 3.75)和终末期肾病(OR 3.42)诊断关联最强。
  • 控制肾脏疾病状态后,APOL1高危变异与非肾脏表型无显著关联。
  • APOL1高危者eGFR较低(15.4 mL/min/1.73m2),且与慢性/终末期肾病/肾移植相关(OR 2.27)。

核心结论

  • APOL1高危变异与多种表型相关,但非肾脏表型风险较低,且在本数据集中由对肾脏疾病的原发效应驱动。

研究设计与样本

  • 基因型优先的全表型组关联研究,纳入1837名Penn Medicine Biobank和4742名Vanderbilt BioVU的非裔美国参与者。
  • Penn Medicine Biobank中使用门诊肌酐测量的eGFR和多变量回归模型评估APOL1高危状态与肾脏结局的关联。

主要发现

  • Meta分析中,APOL1高危变异与「肾脏透析」诊断代码的OR为3.75,与「终末期肾病」的OR为3.42,均高度显著。
  • 仅调整人口学变量时,多个表型与APOL1高危基因型相关;但控制慢性/终末期肾病状态后,非肾脏表型无显著关联。
  • Penn Medicine Biobank中,APOL1高危状态与 prevalent 慢性/终末期肾病/肾移植相关,OR 2.27(95%CI 1.67-3.08)。
  • 高危参与者eGFR为15.4 mL/min/1.73m2,显著低于低危参与者。

临床怎么用

  • 对非裔美国人群进行APOL1高危基因型评估时,应重点关注肾脏疾病筛查与管理。
  • APOL1高危变异与其他系统表型的关联可能继发于肾脏疾病,临床解读需考虑肾脏状态。

局限性

  • 研究基于两个生物样本库的非裔美国参与者,结果外推需谨慎。
  • 非肾脏表型分析受肾脏疾病状态控制的影响,可能掩盖独立关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The relationship between commonly occurring genetic variants (G1 and G2) in the APOL1 gene in African Americans and different disease traits, such as kidney disease, cardiovascular disease, and pre-eclampsia, remains the subject of controversy. Here we took a genotype-first approach, a phenome-wide association study, to define the spectrum of phenotypes associated with APOL1 high-risk variants in 1,837 African American participants of Penn Medicine Biobank and 4,742 African American participants of Vanderbilt BioVU. In the Penn Medicine Biobank, outpatient creatinine measurement-based estimated glomerular filtration rate and multivariable regression models were used to evaluate the association between high-risk APOL1 status and renal outcomes. In meta-analysis of both cohorts, the strongest phenome-wide association study associations were for the high-risk APOL1 variants and diagnoses codes were highly significant for "kidney dialysis" (odds ratio 3.75) and "end stage kidney disease" (odds ratio 3.42). A number of phenotypes were associated with APOL1 high-risk genotypes in an analysis adjusted only for demographic variables. However, no associations were detected with non-renal phenotypes after controlling for chronic/end stage kidney disease status. Using calculated estimated glomerular filtration rate -based phenotype analysis in the Penn Medicine Biobank, APOL1 high-risk status was associated with prevalent chronic/end stage kidney disease /kidney transplant (odds ratio 2.27, 95% confidence interval 1.67-3.08). In high-risk participants, the estimated glomerular filtration rate was 15.4 mL/min/1.73m2; significantly lower than in low-risk participants. Thus, although APOL1 high-risk variants are associated with a range of phenotypes, the risks for other associated phenotypes appear much lower and in our dataset are driven by a primary effect on renal disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Bajaj A, Ihegword A, Qiu C, et al. Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways. Kidney Int. 2020. PMID: 32247630. doi:10.1016/j.kint.2020.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。